SNAI2 and cancer: Sorafenib-resistant PTC showed the most noticeable variation of the cancer stemness marker (KRT17high, KRT19low, ALDH1A1high, PROM1[CD133]high, CD44high, CD24low, and SOX2high), FGF/FGFR (Fibroblast growth factor/Fibroblast growth factor receptors, FGF1, FGF5, FGF11, FGF13, FGF16, FGFR2, FGFR3, and FGFR4), and EMT (SNAIL1, SNAIL2, ZEB1, ZEB2, and TWIST1) (Figure 1B, top, middle, and bottom).